3-methylphenyl 2-methylpropionate | 36438-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-methylphenyl 2-methylpropionate
• 英文别名: m-tolyl isobutyrate；m-Kreyl-isobutyrat；isobutyric acid m-tolyl ester；m-Tolylisobutyrat；Isobuttersaeure-m-tolylester；2-Methylpropionic acid, 3-methylphenyl ester；(3-methylphenyl) 2-methylpropanoate
• CAS: 36438-55-8
• 化学式: C₁₁H₁₄O₂
• mdl: MFCD00748218
• 分子量: 178.231
• InChiKey: CGXNGUPLQGZMAC-UHFFFAOYSA-N

物化性质

• 保留指数：
  1288

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methylphenyl 2-methylpropionate 在 三氯化铝 作用下， 生成 1-(2-hydroxy-4-methylphenyl)-2-methylpropan-1-one
  参考文献：
  名称：

  v. Auwers, Justus Liebigs Annalen der Chemie, 1924, vol. 439, p. 168

  摘要：

  DOI：
• 作为产物：
  描述：

  间甲酚 、 异丁酸 在 Porcine Pancreas Lipase 作用下， 反应 69.0h， 以18.9%的产率得到3-methylphenyl 2-methylpropionate
  参考文献：
  名称：

  Suresh Babu; Karanth; Divakar, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2002, vol. 41, # 5, p. 1068 - 1071

  摘要：

  DOI：

文献信息

• A New and Efficient Esterification Reaction via Mixed Anhydrides by the Promotion of a Catalytic Amount of Lewis Acid
  作者：Mitsutomo Miyashita、Isamu Shiina、So Miyoshi、Teruaki Mukaiyama

  DOI：10.1246/bcsj.66.1516

  日期：1993.5

  In the presence of a catalytic amount of Lewis acid, various carboxylic esters or S-phenyl carbothioates are prepared in excellent yields by the respective reactions of equimolar amounts of silyl carboxylates and alkyl silyl ethers or phenyl silyl sulfides with 4-trifluoromethylbenzoic anhydride.

  在催化量的路易斯酸存在下，通过等摩尔量的甲硅烷基羧酸酯和烷基甲硅烷基醚或苯基甲硅烷基硫化物与4-三氟甲基苯甲酸酐的相应反应，以极好的收率制备各种羧酸酯或S-苯基硫代碳酸酯。
• Thiadiazoline derivative
  申请人：Murakata Chikara

  公开号：US20070213380A1

  公开（公告）日：2007-09-13

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  本发明提供了一种以上述通式(I)所代表的噻二唑衍生物或其药学上可接受的盐为活性成分的抗肿瘤剂。其中R1和R4相同或不同，每个表示氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基或类似物；R5表示取代或未取代的杂环基，取代或未取代的芳基或类似物；R2表示-C(═W)R6或类似物；R3表示氢原子，-C(═WA)R6A或类似物。
• THIADIAZOLINE DERIVATIVE
  申请人：MURAKATA Chikara

  公开号：US20080207706A1

  公开（公告）日：2008-08-28

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其包括由上述一般式（I）表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低碳基，取代或未取代的低炔基，取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物; R2代表-C（═W）R6或类似物; R3代表氢原子，-C（═WA）R6A或类似物。
• Mitotic kinesin inhibitor
  申请人：Murakata Chikara

  公开号：US20070155804A1

  公开（公告）日：2007-07-05

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，其包括由通式（I）表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1代表氢原子等，R2代表氢原子，-C（═W）R6（其中W代表氧原子或硫原子，R6代表取代或未取代的低级烷基等）等，R3代表-C（═Z）R19（其中Z代表氧原子或硫原子，R19代表取代或未取代的低级烷基等）等，R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。
• SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Nuss John N.

  公开号：US20090060912A1

  公开（公告）日：2009-03-05

  Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

  提供了化学式I的化合物，其中变量具有所述的值。药物制剂包括该化合物或其药学上可接受的盐以及药学上可接受的载体和其他药物的组合。治疗患者的方法包括向需要该制剂的患者给予本发明的药物制剂。